# First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699

> **NCT03426995** · PHASE1 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 48 (actual)

## Conditions studied

- Arthritis, Rheumatoid

## Interventions

- **DRUG:** Placebo
- **DRUG:** GSK3358699
- **BIOLOGICAL:** GM-CSF
- **BIOLOGICAL:** LPS
- **OTHER:** Cantharidin

## Key facts

- **NCT ID:** NCT03426995
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-03-13
- **Primary completion:** 2019-05-02
- **Final completion:** 2019-05-02
- **Target enrollment:** 48 (ACTUAL)
- **Why stopped:** The trial was terminated for strategic reasons following the emergence of new data.
- **Last updated:** 2020-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03426995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03426995, "First-time-in-Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single (in Both Fed and Fasted States) or Repeat Doses of GSK3358699". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03426995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*